Autologous stem cell transplant
Subjects who are considered eligible to receive an autologous stem cell transplant
Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start
Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.
Had an autologous transplant within 3 months of starting study drug treatment.
Subjects with lymphoma must have progressed, had stable disease (SD), or recurred after initial treatment regimens that include an anthracycline and an anti-CD20 monoclonal antibody; subjects who relapse >= 12 months after therapy should have progressed after autologous transplant or been ineligible for autologous transplant
Receipt of previous allogeneic stem cell transplant; receipt of previous autologous transplant for AML or non-AML condition is allowed
Patients must have completed an autologous stem cell transplant after their first course of treatment; patients who have relapsed or progressed at any time prior to transplant are not eligible
Chemo-sensitive disease; patients with relapsed plasma cell leukemia may have received systemic therapy including an autologous transplant but it is not required; patients with relapsed multiple myeloma (MM) must have received prior systemic therapy including an autologous transplant; patient must be in at least a PR at the time of transplant; early relapse (VGPR) from complete response will be allowed
Prior autologous stem cell transplant ? 3 months prior to starting CC-90002.
Patients who have undergone autologous stem cell transplant > 6 months prior are eligible
Prior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registration
There is no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplant
Subjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if
Patients with systemic T cell lymphomas who relapsed after autologous transplant are eligible
Patients may not have had a prior autologous or allogeneic transplant
Prior autologous stem cell transplant within 6 months of screening date
Autologous transplant within 6 weeks of planned CAR-T cell infusion.
One prior autologous stem cell transplant within the preceding 12 months.
Patients with systemic T cell lymphomas who relapsed after autologous transplant are eligible
Autologous hematologic stem cell transplant within 6 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Prior autologous stem cell transplant within 6 months of study entry
Patients who have failed a prior autologous transplant are eligible; however, at least 90 days must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous BMT
Autologous transplant must have been done 100 days prior to the study enrollment
Patients whom have undergone previous autologous stem cell transplant, and have recurrent or residual disease are eligible for this trial
One or two prior lines of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, daratumumab, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT])
Prior autologous stem cell transplant within 12 weeks of initiation of therapy
Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.
> 6 months since previous autologous transplant (if applicable)
History of autologous or allogeneic stem cell transplant
Prior treatments: patients must have had at least one prior therapy\r\n* Patients with previous autologous transplant are permitted\r\n* Patients who are eligible and willing to undergo autologous transplant should not be enrolled on this trial\r\n* Prior allogeneic transplant is NOT permitted\r\n* Prior treatment with Brutonâ€™s tyrosine kinase (BTK) inhibitors is NOT permitted\r\n* Prior treatment with nivolumab is permitted
Autologous hematologic stem cell transplant within 3 months of study entry
PRIOR TO CELL PROCUREMENT: Diagnosis of recurrent HL or NHL in patients who have failed > 2 prior treatment regimens; patients relapsed after autologous or allogeneic stem cell transplant are eligible for this study
Subjects must be at least 90 days since autologous stem cell transplant, if performed
Must have a confirmed diagnosis of DLBCL and have progressed following ?2 lines of previous therapy, after autologous stem cell transplant, or not a candidate for autologous stem cell transplant
Autologous stem-cell transplant in the previous six months
Patients may not have had a prior autologous or allogeneic transplant
Recipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria
Patients are eligible 12 weeks after autologous stem cell transplant
Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months
Must not have undergone a prior allogeneic donor (related, unrelated, or cord) transplant; prior autologous transplant is not exclusionary
A prior autologous transplant within 3 months of study entry or allogeneic stem cell transplant
Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation
Prior autologous or allogeneic transplant
Patients who have had a previous autologous or allogeneic stem cell transplant in the previous 12 months
Immunoablative or myeloablative stem cell transplant (SCT): >= 6 months must have elapsed from prior autologous transplant; subjects must not have graft versus host disease post autologous transplant
One prior autologous stem cell transplant within the preceding 12 months
Large-cell lymphoma and aggressive T-cell lymphoma: With chemotherapy sensitive disease that has failed autologous transplant or patients who are ineligible for an autologous transplant; chemotherapy sensitive disease is defined as >= 50% reduction in the size of the tumor with the chemotherapy regimen immediately preceding transplant
Patients who received an autologous stem cell transplant must be ? 3 months post-transplant and all associated toxicities must have resolved to ? CTCAE Grade 1.
Patients who have had a prior autologous transplant are eligible
Allogeneic transplant for AML within the previous 6 months (no time limit for autologous transplant)
Treatment with prior autologous transplant is permitted
Patients who are primarily eligible for autologous stem cell transplant
Patients who have previously undergone autologous stem cell transplant are eligible for this study provided more than 6 months have elapsed from the prior transplant
Prior stem cell transplant (autologous or allogeneic)
Patients who have received a prior autologous or allogeneic transplant are excluded
Patients that have received a prior autologous or allogeneic stem cell transplant
Patients with prior autologous or allogeneic transplant are eligible; patients must be > 100 days post transplant and have no evidence of active GVHD
Prior autologous or allogeneic stem cell transplant
History of autologous or allogeneic stem cell transplant
Prior allogeneic stem cell or autologous transplant.
Prior allogeneic or autologous stem cell transplant
Prior autologous stem cell transplant within 12 weeks
Autologous stem cell transplant less than 90 days prior to study day 1
Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
Patients must have failed autologous stem cell transplant or at least 2 prior cytotoxic regimens for Hodgkin lymphoma; patients who have failed only 1 prior cytotoxic regimen for Hodgkin lymphoma are permitted to enroll as long as they are not eligible for autologous stem cell transplant
Subjects who have previously received an autologous stem cell transplant are allowed if a minimum of 3 months has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2879552.
Subjects may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post transplant.
Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Autologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded
Patients are eligible if an autologous transplant is planned within approximately 12 months from the time of collection of cells
Have received an autologous or allogeneic stem-cell transplant
Prior autologous stem cell transplant ?12 weeks prior to first dose of study drug
Patient received another investigational agent after post autologous stem cell transplant
No autologous or allogeneic stem cell transplant within 3 months prior to cycle 1 day 1
Prior allogeneic transplant (prior autologous stem cell transplant >6 months prior to study entry is permitted)
Patients who have undergone autologous stem cell transplant more than 3 months prior are eligible
Prior autologous stem cell transplant =< 12 weeks prior to registration
Prior autologous or allogeneic transplant
Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;
One prior autologous stem cell transplant within the preceding 12 months
Patients with prior autologous or allogeneic stem cell transplant are eligible as long as they meet all other criteria
Prior autologous stem cell transplant within previous 3 months
Have received autologous stem cell transplant within 12 weeks before the first infusion
Both potentially autologous stem cell transplant (autoSCT) or allogeneic stem cell transplant (alloSCT) candidates and those who are not transplant candidates are eligible for the study
Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
Allogeneic transplant for AML within previous 6 months (no time limit for autologous transplant)
No autologous stem cell transplant within 6 months prior to registration for protocol therapy
Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months
Patients must have a corrected diffusion capacity >= 50% prior to the autologous transplant and >= 40% prior to the allogeneic transplant
Group 3: Have progressive active SSc after prior autologous transplant based on the presence of progressive pulmonary disease; this will be defined by a decrease in the FVC or DLCO adjusted since prior autologous transplant of 15 percent or greater of the pre-transplant percent predicted value, in addition to evidence of alveolitis as defined by chest CT changes or BAL; f patients had prior autologous HCT on the \Scleroderma: Cyclophosphamide Or Transplantation\ (SCOT) clinical trial, they must have failed based on the defined study endpoints and be approved by the protocol principal investigator (PI)
Received autologous stem cell transplant within 28 days or allogeneic transplant within 3 months prior to first dose of study drug
Autologous transplant < 12 months prior to enrollment.
Subjects with prior allogeneic transplant are excluded: however, subjects who have previously received an autologous stem cell transplant are allowed if a minimum of 100 days has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2816126
Prior autologous, peripheral stem cell transplant within 12 weeks of the first dose of study drug.
Received autologous stem cell transplant (ASCT) within 12 months
INCLUSION FOR AUTOLOGOUS STEM CELL COLLECTION (PHASE 1 - TRANSPLANT RECIPIENT):
INCLUSION CRITERIA TO PROCEED WITH AUTOLOGOUS STEM TRANSPLANT (PHASE 2 - TRANSPLANT RECIPIENT):
Patient with a prior stem cell transplant (both autologous and allogeneic)
Eligible for autologous stem cell transplant
Had an autologous transplant within 3 months of starting study drug treatment.
Patients who have received a prior autologous stem cell transplant are eligible if the transplant occurred > 6 months ago.
At least one prior therapy; patients with newly diagnosed tNHL are eligible at the time of transformation; prior autologous stem cell transplant is allowed
Patients eligible for and willing to undergo autologous stem cell transplant with curative intent at the time of enrollment are not eligible
Patients that received an autologous stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.
Treatment with prior autologous transplant is permitted
Prior peripheral autologous stem cell transplant within 12 wks of Baseline.
Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.
Patients must have biopsy proven relapse of a solid tumor or leukemia (for diseases outlined); patients with solid tumors must have failed an autologous transplant or be considered ineligible to receive an autologous transplant because of organ dysfunction or inability to obtain a suitable autologous stem cell collection; in addition, patients will be eligible if their attending physician and transplant physician agree that autologous transplantation would not offer a significant chance of cure (i.e. > 20%); patients with solid tumors must be in complete remission or have minimal residual disease prior to transplant; patients with bulky disease (any single tumor mass measuring > 5 cm in greatest diameter) will not be eligible for this study; select patients with very high-risk solid tumors will be eligible in first complete or partial remission, as indicated below; all subjects with solid tumors who have not had stem cells collected for clinical purposes prior to enrolling on the study will undergo autologous stem cell harvest following standard clinical procedures before beginning the study conditioning regimen
Patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry
NOTE: Prior autologous stem cell transplant as well as prior radiation to CNS does NOT prevent patients from enrollment into the trial
Patient must not have had a previous allogeneic or syngeneic transplant; prior autologous transplant is allowed
All transplant types will be eligible (autologous or allogeneic related or unrelated)
Patients who have received an autologous transplant
One or more prior allogeneic stem cell transplantation (prior autologous transplant is acceptable)
History of an allogeneic stem cell transplant. Subjects with a history of an autologous stem cell transplant are NOT excluded if they meet inclusion criteria related to history of autologous stem cell transplant.
Prior autologous stem cell transplant (ASCT) ? 3 months before first dose.
More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)
Prior autologous or allogeneic stem cell transplant within defined period of initiation of therapy
Autologous stem cell transplant < 90 days prior to study day 1.
Prior autologous stem cell transplant (ASCT) within 6 months preceding Cycle 1 Day 1.
